CA3037883A1 - Anti-cancer agents and preparation thereof - Google Patents
Anti-cancer agents and preparation thereof Download PDFInfo
- Publication number
- CA3037883A1 CA3037883A1 CA3037883A CA3037883A CA3037883A1 CA 3037883 A1 CA3037883 A1 CA 3037883A1 CA 3037883 A CA3037883 A CA 3037883A CA 3037883 A CA3037883 A CA 3037883A CA 3037883 A1 CA3037883 A1 CA 3037883A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- compound
- compounds
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398783P | 2016-09-23 | 2016-09-23 | |
| US62/398,783 | 2016-09-23 | ||
| PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3037883A1 true CA3037883A1 (en) | 2018-03-29 |
Family
ID=61690726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037883A Pending CA3037883A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858371B2 (enExample) |
| EP (1) | EP3515492B1 (enExample) |
| JP (1) | JP7111722B2 (enExample) |
| KR (1) | KR102646702B1 (enExample) |
| CN (1) | CN109862916A (enExample) |
| AU (1) | AU2017331260B2 (enExample) |
| BR (1) | BR112019005885A2 (enExample) |
| CA (1) | CA3037883A1 (enExample) |
| DK (1) | DK3515492T3 (enExample) |
| IL (1) | IL265521B2 (enExample) |
| MA (1) | MA46291A (enExample) |
| MX (1) | MX394670B (enExample) |
| RU (1) | RU2019111768A (enExample) |
| WO (1) | WO2018057897A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2009031999A1 (en) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| WO2009155606A1 (en) * | 2008-06-21 | 2009-12-23 | St. Jude Children's Research Hospital | Anticancer compounds and methods of making and using same |
| US20150025017A1 (en) * | 2012-02-28 | 2015-01-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
| MX340090B (es) * | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| WO2014100367A1 (en) * | 2012-12-21 | 2014-06-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| CN105611930B (zh) | 2013-07-15 | 2021-03-02 | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物 |
| KR102092569B1 (ko) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법 |
| US10000505B2 (en) | 2013-11-19 | 2018-06-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| EP3468976A4 (en) * | 2016-06-08 | 2019-11-27 | William Marsh Rice University | DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF |
| AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-09-22 AU AU2017331260A patent/AU2017331260B2/en active Active
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/ko active Active
- 2017-09-22 MX MX2019003368A patent/MX394670B/es unknown
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/ru unknown
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/da active
- 2017-09-22 IL IL265521A patent/IL265521B2/en unknown
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/zh active Pending
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/pt unknown
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 MA MA046291A patent/MA46291A/fr unknown
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/ja active Active
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en not_active Ceased
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102646702B1 (ko) | 2024-03-11 |
| RU2019111768A (ru) | 2020-10-23 |
| IL265521A (en) | 2019-05-30 |
| IL265521B1 (en) | 2024-05-01 |
| WO2018057897A1 (en) | 2018-03-29 |
| IL265521B2 (en) | 2024-09-01 |
| US20190218228A1 (en) | 2019-07-18 |
| MA46291A (fr) | 2019-07-31 |
| US20210395265A1 (en) | 2021-12-23 |
| AU2017331260A1 (en) | 2019-05-16 |
| EP3515492A1 (en) | 2019-07-31 |
| CN109862916A (zh) | 2019-06-07 |
| JP2019529563A (ja) | 2019-10-17 |
| MX2019003368A (es) | 2019-09-16 |
| AU2017331260B2 (en) | 2024-11-07 |
| BR112019005885A2 (pt) | 2020-06-02 |
| RU2019111768A3 (enExample) | 2020-11-24 |
| EP3515492B1 (en) | 2023-07-26 |
| KR20190077340A (ko) | 2019-07-03 |
| US11851441B2 (en) | 2023-12-26 |
| MX394670B (es) | 2025-03-11 |
| US10858371B2 (en) | 2020-12-08 |
| EP3515492A4 (en) | 2020-04-08 |
| DK3515492T3 (da) | 2023-08-28 |
| JP7111722B2 (ja) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7402549B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| JP2026515630A (ja) | ピリド［４，３－ｄ］ピリミジン化合物 | |
| JP6921101B2 (ja) | プロテインキナーゼ阻害剤及びその調製方法と医薬用途 | |
| AU2023204118B2 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| CA3027495A1 (en) | Cxcr4 inhibitors and uses thereof | |
| CN102234259A (zh) | 含笑内酯衍生物,其药物组合物及其制备方法和用途 | |
| TWI687221B (zh) | 卡奇黴素衍生物及其抗體藥物結合物 | |
| CA3082735A1 (en) | Substituted macrocyclic indole derivatives | |
| CA2931111C (en) | Anti-cancer agents and preparation thereof | |
| EP3515492B1 (en) | Anti-cancer agents and preparation thereof | |
| WO2018089621A1 (en) | Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids | |
| EP3463579B1 (en) | Callyspongiolide, analogs thereof and uses thereof | |
| RU2857665C2 (ru) | Соединения пиридо[4,3-d]пиримидина | |
| JP2026059772A (ja) | ピリド［４，３－ｄ］ピリミジン化合物 | |
| US20230020952A1 (en) | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | |
| HK40006497A (en) | Anti-cancer agents and preparation thereof | |
| WO2025007026A1 (en) | Heterobifunctional compounds and methods of use thereof | |
| HK40128596A (zh) | 吡啶并[4，3-d]嘧啶化合物 | |
| KR20260044145A (ko) | 피리도[4,3-d]피리미딘 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220815 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250327 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250715 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250915 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260507 |